BioPhorum publishes Guidance for ICH Q2(R2) and Q14 Implementation
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
BioPhorum recently published a new document entitled "Best practices for the development, validation and registration of analytical procedures—Implementation of ICH Q2 (R2) and Q14 for biologics." This publication from the end of March 2025 provides recommendations for aligning analytical procedure development and validation practices with the recently updated International Council for Harmonisation (ICH) guidelines Q2(R2) and Q14, which were adopted in late 2023.
The guidance focuses on the integration of Quality by Design (QbD) concepts into analytical procedure development. A central element is the Analytical Target Profile (ATP), which defines the intended purpose of the procedure, the attributes to be measured, and the associated performance criteria.
The 58-page document is structured into the following main chapters:
- Introduction
- Implementing ICH Q14 for the development of analytical procedures
- Validation of analytical procedures
- Conclusion
- Summary tables, glossary, and references
Key aspects discussed in the document include:
- Definition and documentation of the ATP
- Technology selection and the role of the ATP in technology selection
- Analytical procedure development
- Analytical procedure lifecycle management (APLCM)
- Validation strategies
- Use of platform technologies and prior knowledge
The document also provides practical examples and documentation templates to support implementation, such as examples of ATP formulations, technology selection scoring systems, and documentation for parameter range determination.
The authors conclude that "the implementation of ICH Q2 (R2) and Q14 guidelines for the development, validation and registration of analytical procedures represents a significant advancement in the biopharmaceutical industry. By adopting a systematic, risk-based approach, these guidelines ensure that analytical procedures are robust, reliable and fit for their intended purpose throughout the product lifecycle."
The full document is available for download on the BioPhorum website.
Related GMP News
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
14.01.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1


